Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 30, 2006 Stephen D. Simpson	Don't Hold Your Breath for Kensey Nash It's not over for Kensey Nash -- it will soon be seeing revenue from new partners Medtronic and Zimmer. But the stock's price continues to value this company as a growing med-tech idea.
The Motley Fool April 24, 2006 Stephen D. Simpson	Kensey Nash: Now the Comeback Kid? Strong results from a new device might be reason for optimism. Investors should still keep an eye on the valuations here and err on the side of cheapness.
The Motley Fool August 18, 2005 Stephen D. Simpson	Kensey Nash Needs to Kick It Up The med-tech company must deliver profit growth if it is to grow or maintain its valuation.
The Motley Fool December 17, 2011 Stephanie Baum	Kensey Nash Opts for Mediation in Royalties Dispute With St. Jude Kensey Nash withdraws guidance; shares plummet.
The Motley Fool March 17, 2005 Stephen D. Simpson	(G)Nashing of Teeth at Kensey Lower guidance and slower-than-expected FDA approval of TriActiv continue to bedevil this medical device maker.
The Motley Fool August 23, 2006 Stephen D. Simpson	Is Medtronic Sweeping the Deck? Nothing's changing at a deep fundamental level in health care that would impede the growth of this giant med-tech corporation. However, investors need to proceed with caution.
The Motley Fool October 17, 2005 Stephen D. Simpson	A Busy Day for St. Jude In addition to announcing a major acquisition, St. Jude also reported very solid financial results for the third quarter. Analysts keep raising the bar, and the medical equipment company continues to surpass it.
The Motley Fool May 25, 2011 Brian Orelli	No Red Carpet for Medtronic's New CEO Omar Ishrak, Medtronic's newly-appointed CEO, looks like he has his work cut out for him trying to get the medical-device maker growing again.
The Motley Fool July 29, 2011 Brian Orelli	Boston Scientific Shows Me The company has shown it can hit its mark for at least one quarter, but can it last?
The Motley Fool August 4, 2006 Stephen D. Simpson	Medtronic's Shock to the System Its guidance cuts rattled the med-tech industry, but long-term trends remain positive. While the going may be tougher now in the ICD space, it's still an attractive long-term opportunity, and investors may want to start looking around for bargains.
The Motley Fool August 17, 2007 Rich Smith	Foolish Forecast: Kensey Turn It Around? Analysts are looking for just a modest sales increase from Kensey Nash, maker of bio-absorbable arterial sealants, but Kensey hasn't met a target yet this year.
The Motley Fool January 18, 2012 Dan Caplinger	Has St. Jude Medical Become the Perfect Stock? St. Jude took a big step toward perfection when it initiated a big dividend in early 2011.
The Motley Fool April 5, 2006 Stephen D. Simpson	St. Jude's Racing Heartbeat Slows Even though the stock got far too expensive, this is still a good company and could still be a viable target for certain large health-care companies that may be in an acquisition frame of mind.
The Motley Fool February 12, 2010 Brian Orelli	Too Bad It's Not in the "Restructuring" Business Shares of Boston Scientific slipped nearly 10% yesterday, after the company released earnings and guidance for this year.
The Motley Fool January 21, 2005 Stephen D. Simpson	Kensey's Guidance Falls Just Short Small-cap medical device maker posts an "OK" quarter when the market wants "great."
The Motley Fool May 25, 2010 Brian Orelli	Medtronic Gets Tossed Out With the Bathwater A bad day to report good news.
The Motley Fool May 9, 2005 Stephen D. Simpson	Integra LifeSciences Strikes a Nerve The med-tech company's missed quarter coupled with some slightly disappointing guidance caused investors to lose a bit of faith, sending the shares down more than 15% at one point.
The Motley Fool January 6, 2005 Stephen D. Simpson	Can Medtronic Still Quicken the Pulse? While increased competition looms for the medical device maker, a shareholder update looks to the past.
The Motley Fool November 24, 2009 Brian Orelli	52-Week Highs! What's Going On? Even with its recent leap, this stock may belong in your portfolio. Medtronic raised earnings guidance today after a fairly strong quarter, and the stock is hitting new 52-week highs.
The Motley Fool January 27, 2006 Rich Smith	Foolish Forecast: Kensey Grow or Not? The medical technology company's problem is that when you hold your margins more or less steady while your revenues also remain roughly the same, well, everything stays the same. In other words, you can't grow earnings. Investors, take note.
The Motley Fool October 17, 2005 Stephen D. Simpson	A Stimulating Merger St. Jude will be paying $61.25 a share in cash for Advanced Neuromodulation Systems, a robust 30% premium to Friday's closing price. This deal demonstrates that large med-tech players may still be on the prowl for avenues into fast-growing new markets.
The Motley Fool July 26, 2006 Stephen D. Simpson	Aspect Gives Investors Nightmares The med tech company continues to grow, but high volatility is likely to follow.
The Motley Fool August 18, 2005 Stephen D. Simpson	Medtronic Keeps the Beat Strong growth in the ICD and spinal businesses keep Medtronic running. The stock is trading more or less at par to the market with respect to its P/E-to-growth ratio. Investors must decide for themselves whether that's a fair price to pay.
The Motley Fool October 26, 2004 Rich Smith	Kensey's Questionable Call Biomedical products maker Kensey Nash forgets that it is worse to dilute and then buy back shares than never to have diluted at all.
The Motley Fool January 25, 2006 Stephen D. Simpson	Is St. Jude Next to Be Wooed? Can St. Jude build upon the jump-start opportunity from Guidant's troubles, or will further market share growth prove to be increasingly hard to come by? Investors, take note.
The Motley Fool April 19, 2006 Stephen D. Simpson	St. Jude Lives and Learns Though dynamics in the ICD market caught it by surprise, this is still a quality med-tech company. Investors, take note.
The Motley Fool November 15, 2005 Stephen D. Simpson	Guidant, J&J Kiss and Make Up The two companies hammered out a revised merger agreement that continues J&J's buyout of Guidant, but at a lower price. So what does this mean for the med-tech space, assuming that this deal actually goes through? Investors, take note.
The Motley Fool May 5, 2006 Stephen D. Simpson	FoxHollow-ed Out Worries about guidance may be giving investors a second crack at this med-tech stock.
The Motley Fool July 19, 2006 Stephen D. Simpson	Taking St. Jude's Pulse The ICD market is a long-term opportunity, but not a panacea. St. Jude investors should remember that this is a rough neighborhood -- product liability, FDA bureaucracy, and huge, tough competitors live here, too.
The Motley Fool May 8, 2006 Stephen D. Simpson	A Firm Backbone at Kyphon Medtronic begins a lawsuit, but Kyphon should continue to grow. However, these shares are on the expensive side, even for a fast-growing med-tech company.
The Motley Fool October 25, 2007 Billy Fisher	Plenty of Strength in Zimmer Orthopedic manufacturer Zimmer Holdings reports a solid third quarter, but lowers its forecast for Q4.
The Motley Fool January 25, 2006 Stephen D. Simpson	Abbott Wins No matter what Boston Scientific does with Guidant, Abbott looks like a winner. This stock might not offer a rocket ride the way smaller biotechs and med-tech companies do, but at today's prices, at least you won't have to worry about a fiery re-entry.
The Motley Fool January 30, 2009 Brian Orelli	Good Luck in 2010, Zimmer Medical device maker Zimmer met analysts expectations in the fourth quarter, but investors weren't impressed with the company's guidance.
The Motley Fool April 21, 2006 Stephen D. Simpson	Bard Rolls On Nothing flashy here, but at the right price, this would be an interesting med-tech play. Investors, take note.
The Motley Fool October 31, 2005 Stephen D. Simpson	Integra Needs to Grow From Within Acquired growth is nice, but organic growth is the key to long-term success. Quite frankly, the only way this stock works from a cash flow valuation standpoint is if the company does in fact deliver very good growth over the next 10 years or so.
The Motley Fool May 24, 2006 Stephen D. Simpson	Measuring Up Medtronic Everyone loves the med-tech firm. That makes it a dangerous investment.
The Motley Fool May 26, 2005 Stephen D. Simpson	A Second Opinion on Medtronic Medtronic is a growth stalwart, but does valuation properly account for the challenges?
The Motley Fool February 5, 2007 Ryan Fuhrmann	Boston Scientific's Unscientific Outlook There's still uncertainty as the med-tech company blends an acquisition and deals with controversy. Investors, take note.
The Motley Fool June 29, 2006 Jim Mueller	Guidant, Devices, and Recalls, Oh My! To repair its acquisition's good name, Boston Scientific must quickly fix Guidant's problems. One analyst sees annual growth for Guidant's devices in the 10% to 15% range. No one knows how accurate that will prove to be, but it certainly provides hope for the troubled acquisition.
The Motley Fool July 27, 2006 Stephen D. Simpson	Growth Ingrates Dump Intuitive Surgical Despite today's sell-off, Intuitive Surgical remains a red-hot grower in the med-tech space.
The Motley Fool February 2, 2006 Stephen D. Simpson	Cytyc Still Stands On Its Own Despite apparent doubts about some mergers, the med-tech company is still growing strongly. Investors, take note.
The Motley Fool July 20, 2011 Seth Jayson	A Hidden Reason the Future Looks Bright for Kensey Nash The company may display positive inventory divergence, suggesting that management sees increased demand on the horizon.
The Motley Fool August 20, 2004 Rich Smith	Let Kensey Cure Your Portfolio The biomedical products maker is a profit-making machine. This small cap reported outsized profits for fiscal 2004.
The Motley Fool May 25, 2006 Stephen D. Simpson	Same Old Patterson Even deep drilling can't unearth a discount at this dental and veterinary supply distributor. What's more aggravating is having to pay this multiple for the business.
The Motley Fool December 15, 2006 Tom Taulli	Guidance Software: A Lawsuit's Best Friend This software company has found a strong growth channel. While Guidance is definitely solid, it may be worth waiting for the valuation to settle down.
The Motley Fool January 26, 2007 Matthew Crews	Bard's Costly Quarter? The medical device company suffered from multiple one-time charges. Investors who've seen the cup as half full have fared much better here than with many other med-tech companies.
The Motley Fool April 22, 2004 Rich Smith	Kensey Nash Heals Fast Four months was all it took to rejuvinate biomedical products maker Kensey Nash's profit machine.
The Motley Fool July 31, 2006 Stephen D. Simpson	Kinetic Concepts Approaches a Binary Outcome The resolution of a patent infringement trial means far more than one quarter's results for this med-tech company. Investors, take note.
The Motley Fool August 3, 2006 Stephen D. Simpson	Asymmetrical Medical It may pay for investors to be patient with this med-tech company while the industry is in a rough patch.
The Motley Fool September 13, 2005 Stephen D. Simpson	Best Buy Almost a Buy Don't let wobbly quarterly guidance chase you away from one of the best retailers around.